|
| Commercial name (company) | Drug/agent | Delivery system | Indication | Status | Ref. |
|
| Doxil®/Caelyx™ (Schering-Plough; Ortho Biotech) | Doxorubicin | Liposome | Kaposi’s sarcoma; ovarian cancer; multiple myeloma | Approved | [68] |
| Myocet® (Sopherion; Cephalon) | Doxorubicin | Liposome | Metastatic breast cancer | Approved | [68] |
| Lipodox® (Sun) | Doxorubicin | Liposome | Ovarian cancer | Approved | [69] |
| DaunoXome® (Galen) | Daunorubicin | Liposome | Kaposi’s sarcoma | Approved | [70] |
| Marqibo® (Talon; Merrimack) | Vincristine | Liposome | Acute lymphoblastic leukemia | Approved | [68] |
| Onivyde® (Ipsen) | Irinotecan | Liposome | Pancreatic cancer | Approved | [71] |
| Oncaspar® (Enzon) | PEG-L-asparaginase | Polymeric nanoparticles | Acute lymphoblastic leukemia | Approved | [69] |
| Eligard® (Tolmar) | Leuprolide acetate | Polymer (poly(DL-lactide-co-glycolide)) | Prostate cancer | Approved | [72] |
| NanoTherm® (MagForce) | Iron oxide | Iron nanoparticles | Brain tumors | Approved | [73] |
| Abraxane® (Abraxis; AstraZeneca) | Paclitaxel | Albumin-bound nanoparticles | Various cancers | Approved | [68] |
| Rexin-G® (Epeius) | Targeting protein marked phospholipid @ miRNA-122 | Retrovector | Osteosarcoma, pancreatic cancer | Approved | [74] |
| Ontak® (Eisai) | Diphtheria toxin and interleukin 2 bound to liposomes | Protein nanoparticles | T-cell lymphoma | Approved | [75] |
| Vyxeos (Jazz) | Daunorubicin+cytarabine | Liposomes | Acute myeloid leukemia | Approved | [76] |
| Genexol-PM® (Samyang Biopharm) | Paclitaxel | Polymeric micelles | Ovarian cancer | Phase II | [68] |
| LEP-ETU (NeoPharma) | Paclitaxel | Liposomes | Ovarian, breast, lung cancers | Phase I/II | [77] |
| Paclical (Oasmia) | Paclitaxel | Micelles | Ovarian cancer | Phase III | [78] |
| OSI-211 (OSI) | Lurtotecan | Liposomes | Lung, ovarian cancer | Phase II | [79] |
| SGT-53 (SynerGene) | Wild-type p53 gene | Liposomes | Solid tumors; glioblastoma; pancreatic cancer | Phase II | [80] |
| Atragen (Aronex) | All-trans-retinoic acid | Liposomal | Acute promyelocytic leukemia | Phase II | [79] |
| Lipoplatin (Regulon) | Cisplatin | Liposomal | Various cancers | Phase III | [79] |
| Aurimmune (CytImmune Sciences) | TNF-α | Colloidal gold nanoparticles | Solid tumors | Phase II | [79] |
| NK012 (Nippon Kayaku) | 7-Ethyl-10-hydroxycamptothecin | Polymeric micelle | Advanced solid tumor | Phase II | [79] |
| NK105 (Nippon Kayaku) | Paclitaxel | Micelles | Metastatic breast cancer | Phase III | [81] |
| PEP02 (Merrimack) | Irinotecan | Liposomes | Advanced solid tumor | Phase I | [82] |
| CriPec (Cristal) | Docetaxel | Polymeric micelles | Solid tumor | Phase I | [76] |
| CRLX101 (Cerulean) | Camptothecin | Cyclodextrin-based nanoparticles | Non-small-cell lung cancer | Phase II completed | [75] |
| ABI-009 (AADi) | Rapamycin | Albumin-bound nanoparticles | Bladder cancer | Phase I/II | [79] |
| ThermoDox (Celsion) | Doxorubicin | Thermal-sensitive liposomes | Hepatocellular carcinoma | Phase III | [83] |
| CPX-351 (Fred Hutchinson Research Center) | Cytarabine+daunorubicin | Liposomes | Acute myeloid leukemia | Phase I/II | [79] |
| LiPlaCis (Oncology Venture) | Cisplatin | Liposomes | Various cancers | Phase II | [71] |
| PLM60 (CSPC ZhongQi) | Mitoxantrone hydrochloride | Liposomes | Non-Hodgkin lymphoma; breast cancer | Phase I/II | [84] |
| MM-302 (Merrimack) | Trastuzumab | Liposomes | Breast cancer | Phase I | [78] |
| NBTXR3 (Nanobiotix) | Radiotherapy | Hafnium oxide nanoparticles | Liver cancer | Phase I/II | [76] |
| Onco-TCS (Inex) | Vincristine | Liposomes | Non-Hodgkin’s lymphoma | Phase I/II | [79] |
| Aroplatin (Antigenics) | Cisplatin analog | Liposomes | Colorectal cancer | Phase I/II | [79] |
| EndoTAG-I (SynCore Biotechnology) | Paclitaxel | Liposomes | Breast, pancreatic cancers | Phase II | [79] |
| Nektar-102 (Nektar) | Irinotecan | PEGylated liposome | Breast, colorectal cancers | Phase III | [79] |
| NKTR-105 (Nektar) | Docetaxel | PEG-docetaxel | Solid tumor | Phase I | [85] |
|
